| P50 | author | John C. Morris | Q56839763 |
| | Randall J. Bateman | Q39888114 |
| P2093 | author name string | Jingqin Luo | |
| | Chengjie Xiong | |
| P2860 | cites work | Joint modelling of multivariate longitudinal profiles: pitfalls of the random-effects approach. | Q50477793 |
| | Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. | Q51020924 |
| | Cognitive decline in patients with familial Alzheimer's disease associated with E280a presenilin-1 mutation: a longitudinal study. | Q51975332 |
| | Neuropsychological study of familial Alzheimer's disease caused by mutation E280A in the presenilin 1 gene. | Q52007207 |
| | Revising the definition of Alzheimer's disease: a new lexicon. | Q53313597 |
| | [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease | Q60451990 |
| | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| | “Mini-mental state” | Q25938989 |
| | The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers | Q26849380 |
| | Harmonized diagnostic criteria for Alzheimer's disease: recommendations | Q27009157 |
| | Adult age differences in memory performance: tests of an associative deficit hypothesis | Q28139883 |
| | The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 |
| | Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 |
| | Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease | Q30557788 |
| | Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. | Q30561855 |
| | Assessing and interpreting treatment effects in longitudinal clinical trials with missing data | Q30787487 |
| | The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers | Q31081008 |
| | Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease | Q33687554 |
| | Current concepts in mild cognitive impairment | Q34104314 |
| | Editorial: The prevalence and malignancy of Alzheimer disease. A major killer | Q34178758 |
| | Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease | Q34247849 |
| | The preclinical Alzheimer cognitive composite: measuring amyloid-related decline | Q34422469 |
| | Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. | Q34433710 |
| | Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease | Q34509732 |
| | A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group | Q34744744 |
| | A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease | Q35144361 |
| | A phase II trial of huperzine A in mild to moderate Alzheimer disease | Q35719848 |
| | Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia | Q36177038 |
| | Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease | Q37332710 |
| | Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges | Q37352376 |
| | Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease | Q37390862 |
| | Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). | Q37424645 |
| | Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis | Q38220107 |
| | Neuropathology of older persons without cognitive impairment from two community-based studies | Q38405842 |
| | Development of a multiple sclerosis functional composite as a clinical trial outcome measure | Q40810823 |
| | Effects of adult age and working memory on reasoning and spatial abilities | Q41265811 |
| | Frequency of stages of Alzheimer-related lesions in different age categories | Q42445469 |
| | Boston Naming Test: shortened versions for use in Alzheimer's disease | Q46183503 |
| | What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? | Q46349482 |
| | Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 |
| | Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. | Q48552163 |
| | Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation | Q48766227 |
| P433 | issue | 1 | |
| P304 | page(s) | 36-58 | |
| P577 | publication date | 2017-06-02 | |
| P1433 | published in | Biostatistics & Epidemiology | Q63871581 |
| P1476 | title | Linear Combinations of Multiple Outcome Measures to Improve the Power of Efficacy Analysis ---Application to Clinical Trials on Early Stage Alzheimer Disease | |
| P478 | volume | 1 | |